Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma: Study protocol for a systematic review of randomized controlled trial

被引:13
作者
Tang, Qing-xi [1 ]
Wang, Lu-Chuan [1 ]
Wang, Yu [1 ]
Gao, Hong-da [2 ]
Hou, Zhi-ling [3 ]
机构
[1] Jiamusi Hosp Tradit Chinese Med, Orthopedis Dept, Ward 1, Jiamusi, Peoples R China
[2] Jiamusi Cent Hosp, Orthopedis Dept, Ward 1, Jiamusi, Peoples R China
[3] Jiamusi Univ, Dept Emergency Surg, Affiliated Hosp 1, 348 Dexiang St, Jiamusi 154002, Peoples R China
关键词
doxorubicin and cisplatin; efficacy; methotrexate; osteosarcoma; randomized controlled trial; safety; CHEMOTHERAPY; SURVIVAL; METAANALYSIS; EXTREMITIES; NEOADJUVANT; BIAS;
D O I
10.1097/MD.0000000000014442
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:This systematic review will address the efficacy and safety of methotrexate, doxorubicin, and cisplatin (MAP) for the treatment of patients with osteosarcoma.Methods:We will retrieve the studies from the following 9 electronic databases: Cochrane Central Register of Controlled Trials, EMBASE, MEDLINE, the Cumulative Index to Nursing and Allied Health Literature, the Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data. Two independent researchers will screen and select the relevant papers for eligibility after the search strategies have been conducted. All articles up to the present in any language, region will be considered in this study. A systematic review and data synthesis will be performed of randomized controlled trials of MAP for the treatment of patients with osteosarcoma. The primary outcome includes event-free survival. The secondary outcomes consist of overall survival, quality of life, and toxicity. In addition, 2 independent researchers will extract data, and will assess the quality of included studies by using Cochrane risk of bias tool. Results data will be pooled and meta-analysis will be conducted if >2 eligible studies will be included.Results:This systematic review will evaluate the efficacy and safety of MAP for the treatment of patients with osteosarcoma.Conclusion:The findings of this study will summarize the up-to-date evidence of MAP for osteosarcoma, and may provide the guidance for the clinical practice, as well as the health policy maker.PROSPERO registration number:PROSPERO CRD42018120004.
引用
收藏
页数:4
相关论文
共 22 条
[1]  
Bacci G, 2000, ONCOL REP, V7, P339
[2]  
Biazzo A, 2016, ACTA ORTHOP BELG, V82, P690
[3]   Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial [J].
Bielack, Stefan S. ;
Smeland, Sigbjorn ;
Whelan, Jeremy S. ;
Marina, Neyssa ;
Jovic, Gordana ;
Hook, Jane M. ;
Krailo, Mark D. ;
Gebhardt, Mark ;
Papai, Zsuzsanna ;
Meyer, James ;
Nadel, Helen ;
Randall, R. Lor ;
Deffenbaugh, Claudia ;
Nagarajan, Rajaram ;
Brennan, Bernadette ;
Letson, G. Douglas ;
Teot, Lisa A. ;
Goorin, Allen ;
Baumhoer, Daniel ;
Kager, Leo ;
Werner, Mathias ;
Lau, Ching C. ;
Hall, Kirsten Sundby ;
Gelderblom, Hans ;
Meyers, Paul ;
Gorlick, Richard ;
Windhager, Reinhard ;
Helmke, Knut ;
Eriksson, Mikael ;
Hoogerbrugge, Peter M. ;
Schomberg, Paula ;
Tunn, Per-Ulf ;
Kuehne, Thomas ;
Juergens, Heribert ;
van den Berg, Henk ;
Bohling, Tom ;
Picton, Susan ;
Renard, Marleen ;
Reichardt, Peter ;
Gerss, Joachim ;
Butterfass-Bahloul, Trude ;
Morris, Carol ;
Hogendoorn, Pancras C. W. ;
Seddon, Beatrice ;
Calaminus, Gabriele ;
Michelagnoli, Maria ;
Dhooge, Catharina ;
Sydes, Matthew R. ;
Bernstein, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (20) :2279-U92
[4]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[5]   Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma [J].
Fu, Yucheng ;
Lan, Tao ;
Cai, Hongliu ;
Lu, Anwei ;
Yu, Wei .
MEDICINE, 2018, 97 (19)
[6]  
Gorlick R, 2011, PRINCIPLES PRACTICE, P1015
[7]   Tumor Syndromes Predisposing to Osteosarcoma [J].
Hameed, Meera ;
Mandelker, Diana .
ADVANCES IN ANATOMIC PATHOLOGY, 2018, 25 (04) :217-222
[8]   Current and future therapeutic approaches for osteosarcoma [J].
Harrison, Douglas J. ;
Geller, David S. ;
Gill, Jonathan D. ;
Lewis, Valerae O. ;
Gorlick, Richard .
EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) :39-50
[9]  
Jimmy Rincy, 2017, JBI Database System Rev Implement Rep, V15, P2113, DOI 10.11124/JBISRIR-2016-003105
[10]   Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan [J].
Kudawara, Ikuo ;
Aoki, Yasuaki ;
Ueda, Takafumi ;
Araki, Nobuhito ;
Naka, Norifumi ;
Nakanishi, Hirofumi ;
Matsumine, Akihiko ;
Ieguchi, Makoto ;
Mori, Shigeki ;
Myoui, Akira ;
Kuratsu, Shigeyuki ;
Hashimoto, Nobuyuki ;
Yoshikawa, Hideki .
JOURNAL OF CHEMOTHERAPY, 2013, 25 (01) :41-48